UNSPSC 51382602: Lotifazole

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C12H9Cl3N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B3TF200TI, chemically known as 2,2,2-trichloroethyl (4-phenyl-2-thiazolyl)carbamate but generally known as lotifazole, which bears US NIH Compound Identifier 68905. European Medicines Agency schedules Lotifazole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08600MIG.

UNSPSC 51382602 Lotifazole is a Commodity code that in practice receives little recent state and local procurement activity. The single recent opportunity on record—Seminole County, Florida's IFB60459723LAS—involves naloxone and drug deactivation systems rather than lotifazole specifically, indicating a mismatch between the code's nominal scope and the work actually being solicited under it. State and local governments do solicit pharmaceutical products and medical devices through codes in this family, but the present code shows minimal relevant recent activity to support a business development strategy.

Seminole County released IFB60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023. The contract carries a two-year initial term with a one-year renewal option, includes a three-month probationary period, and requires bidders to provide unit costs, maintain specified insurance coverage, complete drug-free workplace certification, and comply with E-Verify requirements. Potential FEMA funding introduces additional federal compliance obligations including adherence to the Clean Air Act and Federal Water Pollution Control Act. The procurement does not identify set-aside designations for disadvantaged enterprises. Given the limited recent activity under this code and the disconnect between its name and the opportunities actually appearing, the code presents minimal pursuit opportunity unless your firm has a specific lotifazole supply capability for health departments or correctional systems.